Literature DB >> 21480387

Dyskerin is required for tumor cell growth through mechanisms that are independent of its role in telomerase and only partially related to its function in precursor rRNA processing.

Faizan Alawi1, Ping Lin.   

Abstract

Dyskerin is an essential nucleolar protein required for the biogenesis of ribonucleoproteins that incorporate H/ACA RNAs. Through binding to specific H/ACA RNAs, dyskerin exerts most of its influence in the cell. To that end, dyskerin is a core component of the telomerase complex and is required for normal telomere maintenance. Dyskerin is also required for post-transcriptional processing of precursor rRNA. Germline dyskerin mutations increase cancer susceptibility. Conversely, wild-type dyskerin is usually over-expressed and not mutated in sporadic cancers. However, the contributions of dyskerin to sporadic tumorigenesis are unknown. Described herein, we demonstrate that acute loss of dyskerin function by RNA interference significantly reduced steady-state levels of H/ACA RNAs, disrupted the morphology and inhibited anchorage-independent growth of telomerase-positive and telomerase-negative human cell lines. Unexpectedly, dyskerin depletion only transiently delayed rRNA maturation but with no appreciable effect on the levels of total 18S or 28S rRNA. Instead, while rRNA processing defects typically trigger p53-dependent G1 arrest, dyskerin-depleted cells accumulated in G2/M by a p53-independent mechanism, and this was associated with an accumulation of aberrant mitotic figures that were characterized by multi-polar spindles. Telomerase activity and the rate of rRNA processing are typically increased during neoplasia. However, our cumulative findings indicate that dyskerin contributes to tumor cell growth through mechanisms which do not require the presence of cellular telomerase activity, and which may be only partially dependent upon the protein's role in rRNA processing. These data also reinforce the notion that loss and gain of dyskerin function may play important roles in tumorigenesis.
Copyright © 2010 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21480387      PMCID: PMC3117972          DOI: 10.1002/mc.20715

Source DB:  PubMed          Journal:  Mol Carcinog        ISSN: 0899-1987            Impact factor:   4.784


  52 in total

Review 1.  The multifunctional nucleolus.

Authors:  François-Michel Boisvert; Silvana van Koningsbruggen; Joaquín Navascués; Angus I Lamond
Journal:  Nat Rev Mol Cell Biol       Date:  2007-07       Impact factor: 94.444

2.  Telomerase RNA level limits telomere maintenance in X-linked dyskeratosis congenita.

Authors:  Judy M Y Wong; Kathleen Collins
Journal:  Genes Dev       Date:  2006-10-02       Impact factor: 11.361

3.  A signature of chromosomal instability inferred from gene expression profiles predicts clinical outcome in multiple human cancers.

Authors:  Scott L Carter; Aron C Eklund; Isaac S Kohane; Lyndsay N Harris; Zoltan Szallasi
Journal:  Nat Genet       Date:  2006-08-20       Impact factor: 38.330

4.  Dyskerin expression influences the level of ribosomal RNA pseudo-uridylation and telomerase RNA component in human breast cancer.

Authors:  L Montanaro; M Brigotti; J Clohessy; S Barbieri; C Ceccarelli; D Santini; M Taffurelli; M Calienni; J Teruya-Feldstein; D Trerè; P P Pandolfi; M Derenzini
Journal:  J Pathol       Date:  2006-09       Impact factor: 7.996

5.  DKC1 is a direct and conserved transcriptional target of c-MYC.

Authors:  Faizan Alawi; Megan N Lee
Journal:  Biochem Biophys Res Commun       Date:  2007-08-24       Impact factor: 3.575

6.  High Skp2 expression characterizes high-risk neuroblastomas independent of MYCN status.

Authors:  Frank Westermann; Kai-Oliver Henrich; Jun S Wei; Werner Lutz; Matthias Fischer; Rainer König; Ruprecht Wiedemeyer; Volker Ehemann; Benedikt Brors; Karen Ernestus; Ivo Leuschner; Axel Benner; Javed Khan; Manfred Schwab
Journal:  Clin Cancer Res       Date:  2007-07-25       Impact factor: 12.531

7.  Different effects of ribosome biogenesis inhibition on cell proliferation in retinoblastoma protein- and p53-deficient and proficient human osteosarcoma cell lines.

Authors:  L Montanaro; G Mazzini; S Barbieri; M Vici; A Nardi-Pantoli; M Govoni; G Donati; D Treré; M Derenzini
Journal:  Cell Prolif       Date:  2007-08       Impact factor: 6.831

8.  Genetic heterogeneity in autosomal recessive dyskeratosis congenita with one subtype due to mutations in the telomerase-associated protein NOP10.

Authors:  Amanda J Walne; Tom Vulliamy; Anna Marrone; Richard Beswick; Michael Kirwan; Yuka Masunari; Fat-Hia Al-Qurashi; Mahmoud Aljurf; Inderjeet Dokal
Journal:  Hum Mol Genet       Date:  2007-05-16       Impact factor: 6.150

9.  Changes in the expression of telomere maintenance genes suggest global telomere dysfunction in B-chronic lymphocytic leukemia.

Authors:  Delphine Poncet; Aurélie Belleville; Claire t'kint de Roodenbeke; Aude Roborel de Climens; Elsa Ben Simon; Hélène Merle-Beral; Evelyne Callet-Bauchu; Gilles Salles; Laure Sabatier; Jozo Delic; Eric Gilson
Journal:  Blood       Date:  2007-12-12       Impact factor: 25.476

Review 10.  Targeting telomerase for cancer therapeutics.

Authors:  J W Shay; W N Keith
Journal:  Br J Cancer       Date:  2008-01-29       Impact factor: 7.640

View more
  20 in total

Review 1.  Small RNAs with big implications: new insights into H/ACA snoRNA function and their role in human disease.

Authors:  Mary McMahon; Adrian Contreras; Davide Ruggero
Journal:  Wiley Interdiscip Rev RNA       Date:  2014-10-31       Impact factor: 9.957

Review 2.  New prospects for targeting telomerase beyond the telomere.

Authors:  Greg M Arndt; Karen L MacKenzie
Journal:  Nat Rev Cancer       Date:  2016-06-24       Impact factor: 60.716

3.  Differential requirements for H/ACA ribonucleoprotein components in cell proliferation and response to DNA damage.

Authors:  Ping Lin; Maral E Mobasher; Yasaman Hakakian; Veena Kakarla; Anum F Naseem; Heliya Ziai; Faizan Alawi
Journal:  Histochem Cell Biol       Date:  2015-08-12       Impact factor: 4.304

4.  Slow growth and unstable ribosomal RNA lacking pseudouridine in mouse embryonic fibroblast cells expressing catalytically inactive dyskerin.

Authors:  Bai-Wei Gu; Jingping Ge; Jian-Meng Fan; Monica Bessler; Philip J Mason
Journal:  FEBS Lett       Date:  2013-05-28       Impact factor: 4.124

5.  Acute dyskerin depletion triggers cellular senescence and renders osteosarcoma cells resistant to genotoxic stress-induced apoptosis.

Authors:  Ping Lin; Maral E Mobasher; Faizan Alawi
Journal:  Biochem Biophys Res Commun       Date:  2014-03-29       Impact factor: 3.575

6.  Zebrafish models for dyskeratosis congenita reveal critical roles of p53 activation contributing to hematopoietic defects through RNA processing.

Authors:  Ying Zhang; Kenji Morimoto; Nadia Danilova; Bo Zhang; Shuo Lin
Journal:  PLoS One       Date:  2012-01-27       Impact factor: 3.240

7.  A novel lncRNA derived from an ultraconserved region: lnc-uc.147, a potential biomarker in luminal A breast cancer.

Authors:  Erika Pereira Zambalde; Recep Bayraktar; Tayana Schultz Jucoski; Cristina Ivan; Ana Carolina Rodrigues; Carolina Mathias; Erik Knutsen; Rubens Silveira de Lima; Daniela Fiori Gradia; Enilze Maria de Souza Fonseca Ribeiro; Samir Hannash; George Adrian Calin; Jaqueline Carvalhode Oliveira
Journal:  RNA Biol       Date:  2021-08-13       Impact factor: 4.766

8.  Dissecting the expression landscape of RNA-binding proteins in human cancers.

Authors:  Bobak Kechavarzi; Sarath Chandra Janga
Journal:  Genome Biol       Date:  2014-01-10       Impact factor: 13.583

9.  Dyskerin overexpression in human hepatocellular carcinoma is associated with advanced clinical stage and poor patient prognosis.

Authors:  Bei Liu; Jinglei Zhang; Chen Huang; Hui Liu
Journal:  PLoS One       Date:  2012-08-13       Impact factor: 3.240

10.  Differential Expression of Non-Shelterin Genes Associated with High Telomerase Levels and Telomere Shortening in Plasma Cell Disorders.

Authors:  Julieta Panero; Flavia Stella; Natalia Schutz; Dorotea Beatriz Fantl; Irma Slavutsky
Journal:  PLoS One       Date:  2015-09-14       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.